HYD LLC Announces New Paper Validating the Anti-Cancer Effect of Deuterium Depletion
HUNGARY, BUDAPEST / ACCESS Newswire / April 7, 2025 /HYD LLC is announcing the publication of a groundbreaking scientific paper that appeared in Biomedicines, validating the therapeutic benefit of deuterium depletion applied in combination with existing cancer treatments. The complementary application of deuterium-depleted water (DDW), as an active agent, multiplies the survival probability of cancer patients. Gábor Somlyai, PhD, molecular biologist, has researched the biological importance of naturally occurring deuterium since 1990 and established HYD LLC for Cancer Research and Drug Development to carry out research, develop, and register deuterium-depleted cancer drugs.
Deuterium Depletion
HYD LLC for Cancer Research and Drug Development released a paper in FEBS Lettersin 1993 based on the research carried out at the National Institute of Oncology (Hungary), proving the regulatory role of deuterium (heavy hydrogen) in cell growth. Since then, several independent studies have confirmed that deuterium depletion, achieved by the replacement of normal water with deuterium-depleted water (DDW), has an anti-cancer effect. Today, it is widely accepted that a submolecular regulatory system exists in the cells that primarily regulates cell growth and metabolism.
HYD LLC was established based on this research, which proved the anti-cancer effect of deuterium depletion and has registered an anti-cancer medicinal product for the treatment of tumorous pets and developed a deuterium-depleted drinking water family (Preventa).
The Benefits of Deuterium Depletion
According to the prognosis, the incidence and deaths caused by cancer will increase by 60-80% by 2050. The company 's drug development strategy offers a viable solution to cancer and metabolic diseases. The scientific paper suggests that integrating deuterium depletion into existing cancer treatment protocols could reduce cancer-related mortality by an unprecedented 75-80%. This marks a historic milestone in oncology-after decades of cancer drug development, this is the first known approach that not only slows disease progression but has the potential to dramatically reduce cancer deaths.
The study is backed by decades of rigorous scientific research. Its high efficacy stems from a fundamentally different mechanism: the therapeutic targeting and modification of the cellular deuterium-hydrogen (D/H) ratio. This submolecular regulatory pathway has been shown to influence cell growth and metabolism, offering a new dimension in cancer therapy and drug development.
Over 30 years ago, Hungarian biologist Gábor Somlyai, PhD, inspired by Hungarian Nobel Laureate Albert Szent-Györgyi-who believed the true cause of cancer must be sought at the submolecular level-began investigating the biological effects of deuterium, aka "heavy hydrogen." His pioneering work laid the foundation for the therapeutic application of deuterium depletion, culminating in the breakthroughs now reported by HYD LLC.
This is the new concept that revealed the pivotal role of the D/H ratio and the high efficacy targeting of the submolecular regulatory system.
The book Deuterium Depletion-A New Way in Curing Cancer and Preserving Health, written by Gábor Somlyai, PhD, summarizes the research of the last 30 years, including protocols for using deuterium-depleted water combined with surgery, radiotherapy, chemotherapy, and hormone therapy.
New Publication
HYD LLC 's latest academic publication presents compelling data demonstrating that integrating deuterium depletion-achieved through the use of commercially available DDW-into conventional cancer therapy significantly increases patient survival rates.
Building on previous findings, including a Phase 2 randomized, double blind clinical trial and several retrospective clinical studies, this new research analyzed outcomes in 2,469 cancer patients who received standard oncological treatments in conjunction with DDW consumption. Survival was the primary endpoint of the study. Among this patient cohort, which represents the Hungarian cancer population, the median survival time was calculated at 11.6 years-nearly five times longer than the national median survival time of 2.4 years for similar patients.
The groundbreaking paper is the culmination of decades of research and clinical trials and is supported by scientific and academic data.
About HYD LLC
HYD LLC is at the forefront of developing innovative cancer therapies based on deuterium depletion, offering a novel approach that complements existing treatments and addresses some of the most pressing challenges in oncology. The company focuses on revealing the role of the naturally occurring deuterium, which has been shown to play a critical role in regulating cell growth and metabolism-a field HYD LLC has been researching for over 35 years.
The company 's drug development strategy targets a central submolecular regulatory system in cells and has already demonstrated a three- to seven-fold increase, depending on cancer type, in patient survival in clinical studies. HYD LLC 's latest academic paper presents data indicating that integrating deuterium depletion into standard cancer therapy could reduce cancer-related mortality by an estimated 75-80%.
HYD LLC is seeking strategic partnerships and investors to continue drug development and successfully close cancer drug registration. The approach for deuterium depletion has a strong synergistic effect with the current pharmaceutical modalities.
This groundbreaking research represents a major breakthrough in cancer treatment and opens a new frontier in precision oncology.
Media Contact:
Company:HYD for Cancer Research and Drug Development LLC.
Email:ddw@hyd.hu
Website:https://hyd.hu/en/
Address:Villányi út 97., Budapest,1118Hungary
SOURCE:HYD for Cancer Research and Drug Development LLC.
View the original press release on ACCESS Newswire
© 2025 ACCESS Newswire. All Rights Reserved.
